Akeso (AKESF) announced that its supplemental New Drug Application, sNDA, for gumokimab, AK111, has been accepted for review by the Center for Drug Evaluation, CDE, of the National Medical Products Administration, NMPA. Active ankylosing spondylitis is the second indication for which gumokimab has gained acceptance for NDA review. The application for its use in treating moderate-to-severe psoriasis was previously accepted by the CDE in January 2025.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKESF: